Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
An assessment of the mechanistic differences between two integrin alpha 4 beta 1 inhibitors, the monoclonal antibody TA-2 and the small molecule BIO5192, in rat experimental autoimmune encephalomyelitis.
Leone DR, Giza K, Gill A, Dolinski BM, Yang W, Perper S, Scott DM, Lee WC, Cornebise M, Wortham K, Nickerson-Nutter C, Chen LL, LePage D, Spell JC, Whalley ET, Petter RC, Adams SP, Lobb RR, Pepinsky RB. Leone DR, et al. J Pharmacol Exp Ther. 2003 Jun;305(3):1150-62. doi: 10.1124/jpet.102.047332. Epub 2003 Mar 6. J Pharmacol Exp Ther. 2003. PMID: 12626659
Design, synthesis, and analysis of a polyethelene glycol-modified (PEGylated) small molecule inhibitor of integrin {alpha}4{beta}1 with improved pharmaceutical properties.
Pepinsky RB, Lee WC, Cornebise M, Gill A, Wortham K, Chen LL, Leone DR, Giza K, Dolinski BM, Perper S, Nickerson-Nutter C, Lepage D, Chakraborty A, Whalley ET, Petter RC, Adams SP, Lobb RR, Scott DM. Pepinsky RB, et al. J Pharmacol Exp Ther. 2005 Feb;312(2):742-50. doi: 10.1124/jpet.104.075648. Epub 2004 Oct 14. J Pharmacol Exp Ther. 2005. PMID: 15485895
Antibody-mediated blockade of integrin alpha v beta 6 inhibits tumor progression in vivo by a transforming growth factor-beta-regulated mechanism.
Van Aarsen LA, Leone DR, Ho S, Dolinski BM, McCoon PE, LePage DJ, Kelly R, Heaney G, Rayhorn P, Reid C, Simon KJ, Horan GS, Tao N, Gardner HA, Skelly MM, Gown AM, Thomas GJ, Weinreb PH, Fawell SE, Violette SM. Van Aarsen LA, et al. Among authors: lepage dj. Cancer Res. 2008 Jan 15;68(2):561-70. doi: 10.1158/0008-5472.CAN-07-2307. Cancer Res. 2008. PMID: 18199553
Targeting the lymphotoxin-beta receptor with agonist antibodies as a potential cancer therapy.
Lukashev M, LePage D, Wilson C, Bailly V, Garber E, Lukashin A, Ngam-ek A, Zeng W, Allaire N, Perrin S, Xu X, Szeliga K, Wortham K, Kelly R, Bottiglio C, Ding J, Griffith L, Heaney G, Silverio E, Yang W, Jarpe M, Fawell S, Reff M, Carmillo A, Miatkowski K, Amatucci J, Crowell T, Prentice H, Meier W, Violette SM, Mackay F, Yang D, Hoffman R, Browning JL. Lukashev M, et al. Cancer Res. 2006 Oct 1;66(19):9617-24. doi: 10.1158/0008-5472.CAN-06-0217. Cancer Res. 2006. PMID: 17018619
Antibody blockade of the Cripto CFC domain suppresses tumor cell growth in vivo.
Adkins HB, Bianco C, Schiffer SG, Rayhorn P, Zafari M, Cheung AE, Orozco O, Olson D, De Luca A, Chen LL, Miatkowski K, Benjamin C, Normanno N, Williams KP, Jarpe M, LePage D, Salomon D, Sanicola M. Adkins HB, et al. J Clin Invest. 2003 Aug;112(4):575-87. doi: 10.1172/JCI17788. J Clin Invest. 2003. PMID: 12925698 Free PMC article.
17 results